Optimization of time to initial vancomycin target trough improves clinical outcomes

Area of Science:

• Pharmacology and Therapeutics
• Infectious Diseases
• Clinical Pharmacy

Background:

• Limited data exists on the efficacy of interventions aimed at reducing the time to achieve initial target vancomycin troughs.
• Optimizing vancomycin dosing is crucial for effective treatment of serious bacterial infections, particularly those caused by Gram-positive organisms.

Purpose of the Study:

• To evaluate the impact of a vancomycin therapeutic drug monitoring (TDM) program on the time to initial target troughs.
• To assess the effect of the TDM program on key clinical outcomes in adult inpatients.
• To ensure the safety of the TDM program by analyzing rates of nephrotoxicity.

Main Methods:

• A single-center, pre- and post-intervention observational study was conducted.
• Adult inpatients received either physician-guided vancomycin therapy (historical control, CTRL) or pharmacist-guided vancomycin therapy via a TDM program.
• Clinical outcomes were analyzed in patients with normal renal function and culture-confirmed Gram-positive infections, including a Methicillin-resistant Staphylococcus aureus (MRSA) subset. Nephrotoxicity was also assessed.

Main Results:

• The TDM group achieved initial target vancomycin troughs significantly faster (3 days) compared to the control group (5 days).
• Patients in the TDM group experienced shorter hospital stays (7 vs. 14 days), faster clinical stability (4 vs. 8 days), and reduced vancomycin treatment duration (4 vs. 7 days).
• Similar rates of acute kidney injury were observed between the TDM and CTRL groups. In the MRSA subset, TDM was associated with more rapid hospital discharge, clinical stability, and shorter vancomycin courses.

Conclusions:

• Interventions focused on decreasing the time to reach initial target vancomycin troughs can enhance clinical outcomes.
• The TDM program demonstrated significant benefits for patients with Gram-positive infections, particularly MRSA infections.
• The TDM program is a safe and effective strategy for optimizing vancomycin therapy.